Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity [published online ahead of print, 2022 Jan 26]. Nat Rev Clin Oncol 19:254–267

Article  PubMed  PubMed Central  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38

Article  PubMed  PubMed Central  Google Scholar 

Shen P, Deng X, Hu Z et al (2021) Rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy. Front Med (Lausanne) 8:762247

Article  PubMed  Google Scholar 

Kostine M, Truchetet ME, Schaeverbeke T (2019) Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford) 58(Suppl 7):vii68–vii74

Article  CAS  PubMed  Google Scholar 

Daxini A, Cronin K, Sreih AG (2018) Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol 37(9):2579–2584

Article  PubMed  Google Scholar 

Crout TM, Lennep DS, Kishore S, Majithia V (2019) Systemic vasculitis associated with immune check point inhibition: analysis and review. Curr Rheumatol Rep 21(6):28

Article  PubMed  Google Scholar 

Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med 169:133–134

Article  PubMed  Google Scholar 

Park HJ, Ranganathan P (2011) Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am 37:593–606

Article  PubMed  Google Scholar 

Roy AK, Tathireddy HR, Roy M (2017) Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep 2017:bcr2017221852

Article  PubMed  PubMed Central  Google Scholar 

Loricera J, Hernández JL, García-Castaño A, Martínez-Rodríguez I, González-Gay MÁ, Blanco R (2018) Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis? Clin Exp Rheumatol 36(2):171

PubMed  Google Scholar 

Hotta M, Naka G, Minamimoto R, Takeda Y, Hojo M (2020) Nivolumab-induced periaortitis demonstrated by FDG PET/CT. Clin Nucl Med 45(11):910–912

Article  PubMed  Google Scholar 

Henderson D, Eslamian G, Poon D, Crabb S, Jones R, Sankey P, Kularatne B, Linch M, Josephs D (2020) Immune checkpoint inhibitor induced large vessel vasculitis. BMJ Case Rep 13(5):e233496. https://doi.org/10.1136/bcr-2019-233496. (Corrected and republished in: Drug Ther Bull. 2021 Feb;59(2):29–31)

Article  PubMed  PubMed Central  Google Scholar 

Ban BH, Crowe J, Graham RM (2017) Rheumatology case report immune-related aortitis associated with ipilimumab. Rheumatologist

Pinkston O, Berianu F, Wang B (2016) Type and frequency of immune-related adverse reactions in patients treated with pembrolizumab (Keytruda), a monoclonal antibody directed against PD-1, in Advanced melanoma at a single institution [abstract]. Arthritis Rheumatol 68(suppl 10)

Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM (2017) Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci USA 114(6):E970–E979

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM (2017) Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 312(5):H1052–H1059. https://doi.org/10.1152/ajpheart.00024.2017

Article  PubMed  PubMed Central  Google Scholar